Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report

BACKGROUND: Recent advances in cancer immunotherapy have been remarkable, with many reports on the clinical effects of immune checkpoint inhibitors. Nivolumab has been covered by the national health insurance in Japan as a third-line agent for advanced and recurrent gastric cancer since September 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Takami, Tomoya, Yasuda, Koji, Uozumi, Nozomi, Musiake, Yutaka, Shintani, Hiroshi, Kataoka, Naoki, Yamaguchi, Tomoyuki, Makimoto, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690463/
https://www.ncbi.nlm.nih.gov/pubmed/34930435
http://dx.doi.org/10.1186/s13256-021-03200-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690463/
https://www.ncbi.nlm.nih.gov/pubmed/34930435
http://dx.doi.org/10.1186/s13256-021-03200-x

Ejemplares similares